1. Home
  2. XBIO vs SPHL Comparison

XBIO vs SPHL Comparison

Compare XBIO & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XBIO
  • SPHL
  • Stock Information
  • Founded
  • XBIO N/A
  • SPHL 2002
  • Country
  • XBIO United States
  • SPHL Singapore
  • Employees
  • XBIO N/A
  • SPHL N/A
  • Industry
  • XBIO Biotechnology: Pharmaceutical Preparations
  • SPHL Homebuilding
  • Sector
  • XBIO Health Care
  • SPHL Consumer Discretionary
  • Exchange
  • XBIO Nasdaq
  • SPHL Nasdaq
  • Market Cap
  • XBIO 4.4M
  • SPHL 4.9M
  • IPO Year
  • XBIO N/A
  • SPHL 2024
  • Fundamental
  • Price
  • XBIO $10.30
  • SPHL $0.63
  • Analyst Decision
  • XBIO Hold
  • SPHL
  • Analyst Count
  • XBIO 1
  • SPHL 0
  • Target Price
  • XBIO N/A
  • SPHL N/A
  • AVG Volume (30 Days)
  • XBIO 28.4K
  • SPHL 3.4M
  • Earning Date
  • XBIO 11-11-2025
  • SPHL 10-28-2025
  • Dividend Yield
  • XBIO N/A
  • SPHL N/A
  • EPS Growth
  • XBIO N/A
  • SPHL N/A
  • EPS
  • XBIO N/A
  • SPHL N/A
  • Revenue
  • XBIO $2,446,221.00
  • SPHL $5,956,226.00
  • Revenue This Year
  • XBIO $1.99
  • SPHL N/A
  • Revenue Next Year
  • XBIO $20.00
  • SPHL N/A
  • P/E Ratio
  • XBIO N/A
  • SPHL N/A
  • Revenue Growth
  • XBIO N/A
  • SPHL N/A
  • 52 Week Low
  • XBIO $2.20
  • SPHL $0.35
  • 52 Week High
  • XBIO $5.27
  • SPHL $7.80
  • Technical
  • Relative Strength Index (RSI)
  • XBIO 95.26
  • SPHL 52.05
  • Support Level
  • XBIO $2.81
  • SPHL $0.52
  • Resistance Level
  • XBIO $3.29
  • SPHL $0.68
  • Average True Range (ATR)
  • XBIO 0.40
  • SPHL 0.09
  • MACD
  • XBIO 0.63
  • SPHL 0.01
  • Stochastic Oscillator
  • XBIO 100.00
  • SPHL 38.50

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.

Share on Social Networks: